Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2015

01-01-2015 | Endocrine Tumors

Biochemical Cure after Reoperations for Medullary Thyroid Carcinoma: A Meta-analysis

Authors: Kathryn J. Rowland, MD, MPHS, Linda X. Jin, MD, Jeffrey F. Moley, MD

Published in: Annals of Surgical Oncology | Issue 1/2015

Login to get access

Abstract

Background

Despite meticulous surgical techniques, calcitonin levels remain detectable in 40 % to 66 % of patients after initial surgery for medullary thyroid carcinoma (MTC), and the optimal surgical management for persistent or recurrent disease remains controversial. Previous studies suggest that biochemical cure, defined by normalization of postoperative calcitonin measurements, predicts disease-free survival. Reoperative approaches range from targeted removal of detectable disease to comprehensive compartment-oriented lymph node clearance.

Methods

A proportional meta-analysis of clinical case series of postoperative calcitonin clearance after reoperation for MTC was performed. Studies were obtained from PubMed, Embase, Scopus, and the Cochrane Library.

Results

Twenty-seven articles capturing data of 984 patients met the inclusion criteria for the meta-analysis. Overall, normalization of calcitonin after reoperation for MTC occurred in 16.2 % of patients [95 % confidence interval (CI) 14.0–18.5]. Stratified by operative procedure, targeted selective lymph node removal procedures had a normalization of calcitonin in 10.5 % of patients (95 % CI 6.4–14.7), while compartment-oriented procedures had a higher rate of normalization at 18.6 % (95 % CI 15.9–21.3).

Conclusions

The rate of calcitonin normalization after reoperation for MTC is enhanced through use of a meticulous compartment-oriented lymph node dissection. Compartment-oriented lymph node dissection results in calcitonin normalization in 18.6 % of reoperative MTC patients and is the procedure of choice in patients in whom the goal is biochemical cure.
Literature
1.
2.
Wells SA Jr, Baylin SB, Linehan WM, Farrell RE, Cox EB, Cooper CW. Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann Surg. 1978;188:139–41.PubMedCentralPubMedCrossRef
3.
4.
Normann T. Medullary thyroid carcinoma in Norway. Acta Pathol Microbiol Scand A. 1977;85:775–86.PubMed
5.
Ruggiero FP, Fedok FG. Outcomes in reoperative thyroid cancer. Otolaryngol Clin North Am. 2008;41:1261–8.PubMedCrossRef
6.
Fialkowski EA, Moley JF. Current approaches to medullary thyroid carcinoma, sporadic and familial. J Surg Oncol. 2006;94:737–47.PubMedCrossRef
7.
Ukkat J, Gimm O, Brauckhoff M, Bilkenroth U, Dralle H. Single center experience in primary surgery for medullary thyroid carcinoma. World J Surg. 2004;28:1271–4.PubMedCrossRef
8.
Weber T, Schilling T, Frank-Raue K, et al. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery. 2001;130:1044–9.PubMedCrossRef
9.
Rendl G, Manzl M, Hitzl W, Sungler P, Pirich C. Long-term prognosis of medullary thyroid carcinoma. Clin Endocrinol. 2008;69:497–505.CrossRef
10.
Melvin KE, Miller HH, Tashjian AH Jr. Early diagnosis of medullary carcinoma of the thyroid gland by means of calcitonin assay. N Engl J Med. 1971;285:1115–20.PubMedCrossRef
11.
de Groot JW, Plukker JT, Wolffenbuttel BH, Wiggers T, Sluiter WJ, Links TP. Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol. 2006;65:729–36.PubMedCrossRef
12.
Pellegriti G, Leboulleux S, Baudin E, et al. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer. 2003;88:1537–42.PubMedCentralPubMedCrossRef
13.
Fialkowski E, Debenedetti M, Moley J. Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg. 2008;32:754–65.PubMedCrossRef
14.
Dotzenrath C, Goretzki PE, Cupisti K, et al. Is there any consensus in diagnostic and operative strategy with respect to medullary thyroid cancer? A questionnaire answered by 73 endocrine surgical units. Langenbecks Arch Surg. 2001;386:47–52.PubMedCrossRef
15.
Abdelmoumene N, Schlumberger M, Gardet P, et al. Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma. Br J Cancer. 1994;69:1141–4.PubMedCentralPubMedCrossRef
16.
Ben Mrad MD, Gardet P, Roche A, et al. Value of venous catheterization and calcitonin studies in the treatment and management of clinically inapparent medullary thyroid carcinoma. Cancer. 1989;63:133–8.
17.
Block MA, Jackson CE, Tashjian AH Jr. Management of occult medullary thyroid carcinoma: evidenced only by serum calcitonin level elevations after apparently adequate neck operations. Arch Surg. 1978;113:368–72.PubMedCrossRef
18.
Brumsen C, Haak HR, Goslings BM, van de Velde CJ. Should patients with medullary thyroid carcinoma undergo extensive lymph node (re)operation to improve long-term survival? Henry Ford Hosp Med J. 1992;40:271–5.PubMed
19.
Buhr HJ, Kallinowski F, Raue F, Frank-Raue K, Herfarth C. Microsurgical neck dissection for metastasizing medullary thyroid carcinoma. Eur J Surg Oncol. 1995;21:195–7.PubMedCrossRef
20.
Buhr HJ, Lehnert T, Raue F. New operative strategy in the treatment of metastasizing medullary carcinoma of the thyroid. Eur J Surg Oncol. 1990;16:366–9.PubMed
21.
De Groot JWB, Links TP, Jager PL, Kahraman T, Plukker JTM. Impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol. 2004;11:786–94.PubMedCrossRef
22.
De Groot JWB, Links TP, Sluiter WJ, Wolffenbuttel BHR, Wiggers T, Plukker JTM. Locoregional control in patients with palpable medullary thyroid cancer: results of standardized compartment-oriented surgery. Head Neck. 2007;29:857–63.PubMedCrossRef
23.
De Labriolle-Vaylet C, Cattan P, Sarfati E, et al. Successful surgical removal of occult metastases of medullary thyroid carcinoma recurrences with the help of immunoscintigraphy and radioimmunoguided surgery. Clin Cancer Res. 2000;6:363–71.PubMed
24.
Decker RA. Long-term follow-up of a large North American kindred with multiple endocrine neoplasia type 2A. Surgery. 1992;112:1066–72.PubMed
25.
Dralle H, Damm I, Scheumann GF, Kotzerke J, Kupsch E. Frequency and significance of cervicomediastinal lymph node metastases in medullary thyroid carcinoma: results of a compartment-oriented microdissection method. Henry Ford Hosp Med J. 1992;40:264–7.PubMed
26.
Dralle H, Damm I, Scheumann GF, et al. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today. 1994;24:112–21.PubMedCrossRef
27.
Duh QY, Sancho JJ, Greenspan FS, et al. Medullary thyroid carcinoma. The need for early diagnosis and total thyroidectomy. Arch Surg. 1989;124:1206–10.PubMedCrossRef
28.
29.
Frank-Raue K, Raue F, Buhr HJ, Baldauf G, Lorenz D, Ziegler R. Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization. Thyroid. 1992;2:113–7.PubMedCrossRef
30.
Gimm O, Dralle H. Reoperation in metastasizing medullary thyroid carcinoma: is a tumor stage-oriented approach justified? Surgery. 1997;122:1124–30.PubMedCrossRef
31.
Gimm O, Ukkat J, Dralle H. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg. 1998;22:562–7.PubMedCrossRef
32.
Goltzman D, Potts JT Jr, Ridgway RC, Maloof F. Calcitonin as a tumor marker. Use of the radioimmunoassay for calcitonin in the postoperative evaluation of patients with medullary thyroid carcinoma. N Engl J Med. 1974;290:1035–9.PubMedCrossRef
33.
Jeng TK, Lee CH, Wang HC, Chiu JW, Lui WY. DNA analysis and persistent hypercalcitoninemia in medullary thyroid carcinoma. Zhonghua Yi Xue Za Zhi (Taipei). 1993;51:340–4.PubMed
34.
Kallinowski F, Buhr HJ, Meybier H, Eberhardt M, Herfarth C. Medullary carcinoma of the thyroid—therapeutic strategy derived from fifteen years of experience. Surgery. 1993;114:491–6.PubMed
35.
Kebebew E, Kikuchi S, Duh QY, Clark OH. Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg. 2000;135:895–901.PubMedCrossRef
36.
Machens A, Dralle H. Benefit–risk balance of reoperation for persistent medullary thyroid cancer. Ann Surg. 2013;257(4):751–7.
37.
Marzano LA, Porcelli A, Biondi B, et al. Surgical management and follow-up of medullary thyroid carcinoma. J Surg Oncol. 1995;59:162–8.PubMedCrossRef
38.
Medina-Franco H, Herrera MF, López Ch G, et al. Persistent hypercalcitoninemia in patients with medullary thyroid cancer: a therapeutic approach based on selective venous sampling for calcitonin. Rev Invest Clin. 2001;53:212–7.PubMed
39.
Misso C, Calzolari F, Puxeddu E, et al. Persistent hypercalcitoninemia in patients with medullary thyroid cancer. Tumori. 2009;95:484–7.PubMed
40.
41.
Moley JF, Wells SA, Dilley WG, Tisell LE. Reoperation for recurrent or persistent medullary thyroid cancer. Surgery. 1993;114:1090–5.PubMed
42.
Norton JA, Doppman JL, Brennan MF. Localization and resection of clinically inapparent medullary carcinoma of the thyroid. Surgery. 1980;87:616–22.PubMed
43.
O’Riordain DS, O’Brien T, Weaver AL, et al. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery. 1994;116:1017–23.PubMed
44.
Pelizzo MR, Bernante P, Piotto A, et al. The extent of surgery for thyroid medullary cancer. Tumori. 1994;80:427–32.PubMed
45.
Raue F, Winter J, Frank-Raue K, Lorenz D, Herfarth C, Ziegler R. Diagnostic procedure before reoperation in patients with medullary thyroid carcinoma. Horm Metab Res Suppl. 1989;21:31–4.PubMed
46.
Schott M, Willenberg HS, Sagert C, et al. Identification of occult metastases of medullary thyroid carcinoma by pentagastrin-stimulated intravenous calcitonin sampling followed by targeted surgery. Clin Endocrinol. 2007;66:405–9.CrossRef
47.
Tisell LE, Hansson G, Jansson S, Salander H. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery. 1986;99:60–6.PubMed
48.
Tisell LE, Jansson S. Recent results of reoperative surgery in medullary carcinoma of the thyroid. Wien Klin Wochenschr. 1988;100:347–8.PubMed
49.
van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg. 1990;212:395–400.PubMedCentralPubMedCrossRef
50.
Vila JMF, Peix JL, Mandry AC, Mezzadri NA, Lifante JC. Biochemical results of reoperations for medullary thyroid carcinoma. Laryngoscope. 2007;117:886–9.CrossRef
51.
Voutilainen PE, Multanen M, Haapiainen RK, Haglund CH, Sane T, Sivula AH. Long term prognosis of medullary thyroid carcinoma in 39 patients. Ann Chir Gynaecol. 2000;89:292–7.PubMed
52.
Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery. 2003;134:890–9.PubMedCrossRef
53.
Cupisti K, Wolf A, Raffel A, et al. Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution’s experience over 20 years. Ann Surg. 2007;246:815–21.PubMedCrossRef
54.
Moses L. The series of consecutive cases as a device for assessing outcomes of interventions. In: Bailar J, Hoaglin D, editors. Medical uses of statistics. 3rd ed. New York: Wiley; 2009. p. 109–22.
55.
Meijer JA, le Cessie S, van den Hout WB, et al. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol. 2010;72:534–42.PubMedCrossRef
Metadata
Title
Biochemical Cure after Reoperations for Medullary Thyroid Carcinoma: A Meta-analysis
Authors
Kathryn J. Rowland, MD, MPHS
Linda X. Jin, MD
Jeffrey F. Moley, MD
Publication date
01-01-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 1/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4102-y

Other articles of this Issue 1/2015

Annals of Surgical Oncology 1/2015 Go to the issue

Breast Oncology

Prognostic Value of Extracapsular Invasion of Axillary Lymph Nodes Combined with Peritumoral Vascular Invasion in Patients with Breast Cancer

Breast Oncology

Surgical Patterns of Care in Patients with Invasive Breast Cancer Treated with Neoadjuvant Systemic Therapy and Breast Magnetic Resonance Imaging: Results of a Secondary Analysis of TBCRC 017

Thoracic Oncology

Cumulative Prognostic Scores Based on Plasma Fibrinogen and Serum Albumin Levels in Esophageal Cancer Patients Treated with Transthoracic Esophagectomy: Comparison with the Glasgow Prognostic Score

Gastrointestinal Oncology

Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer

Breast Oncology

The Utility of Sentinel Lymph Node Biopsy in Patients with Ductal Carcinoma In Situ Suspicious for Microinvasion on Core Biopsy

Thoracic Oncology

Prognostic Significance of Lymphovascular Invasion in Patients with Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy